Genetic study of outcomes in cardiogenic shock
Part of Heart & circulation clinical trials.
This study looks at whether a person’s genetic information (genomics) can help predict outcomes in cardiogenic shock. You may be asked to give consent and provide information during a serious heart-related emergency, usually soon after symptoms start.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You (or your legal representative) can consent to take part in the study.
- Your cardiogenic shock must start within 24 hours of your heart-symptom start.
- Your shock must be caused by a heart attack (STEMI or NSTEMI), or by myocarditis—not another cause.
- You must have plans or have already had treatment to reopen the blocked heart artery (revascularisation) after the event.
- You must meet the study’s shock measures: very low blood pressure for at least 30 minutes and needing medicines (vasopressors/inotropes) to keep blood pressure up, plus signs of poor organ function (like confusion, cold/clammy skin, very low urine, or higher lactate).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tracks how well people with cardiogenic shock (a life-threatening drop in blood flow after a heart attack or heart failure worsening) do when treated with modern support devices and medicines.
This study looks at how people with cardiogenic shock (or very low blood pressure from heart causes) do after treatment in a specialized cardiovascular ICU. It also examines whether care by heart critical-care specialists affects outcomes.
This registry tracks patients experiencing cardiogenic shock—a serious condition where the heart suddenly cannot pump enough blood to the body. Researchers collect information about patient outcomes and treatments to better understand what helps people recover.
This trial is testing different approaches (medications and mechanical support) to help people with acute heart failure and cardiogenic shock (a sudden drop in the heart's pumping ability). It looks at how well these treatments work in a network of hospitals to improve outcomes.
This trial looks at what happens to people after they survive a serious heart condition called cardiogenic shock, where the heart suddenly can't pump enough blood. Researchers want to understand recovery and improve care for survivors.
This study is a “registry,” meaning it collects health information from people hospitalized with cardiogenic shock. It may help doctors better understand the condition and improve care over time.
Hear when a new Cardiogenic Shock trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.